Safety, efficacy, and pharmacokinetics of golimumab in patients with moderately to severely Active ulcerative colitis: PURSUIT-SC long-term extension

被引：0

作者：

Reinisch, W. ^{[1
,2
,3
,4
]}

Gibson, P. ^{[5
]}

Sandborn, W. J. ^{[6
]}

Feagan, B. ^{[7
]}

Marano, C. ^{[8
]}

Strauss, R. ^{[8
]}

Johanns, J. ^{[8
]}

Zhang, H. ^{[8
]}

Padgett, L. ^{[8
]}

Adedokun, O. J. ^{[8
]}

Colombel, J. -F. ^{[9
]}

Collins, J. ^{[10
]}

Rutgeerts, P. ^{[11
]}

Tarabar, D. ^{[12
]}

机构：

[1] Univ Klin Innere Med III, Vienna, Austria

[2] McMaster Univ, Vienna, Austria

[3] Univ Klin Innere Med III, Hamilton, Austria

[4] McMaster Univ, Hamilton, Austria

[5] Alfred Hosp, Melbourne, Vic, Australia

[6] Univ Calif San Diego, Div Gastroenterol, La Jolla, CA 92093 USA

[7] Univ Western Ontario, Robarts Res Inst, Robarts Clin Trials Inc, London, ON, Canada

[8] Janssen R&D LLC, Spring House, PA USA

[9] Icahn Sch Med Mt Sinai, New York, NY 10029 USA

[10] Oregon Hlth & Sci Univ, Dept Gastroenterol, Portland, OR USA

[11] Univ Hosp Gasthuisberg, Dept Haematol, Leuven, Netherlands

[12] Mil Med Acad, Dept Gastroenterol & Hepatol, Belgrade 11002, Serbia

来源：

JOURNAL OF CROHNS & COLITIS | 2016年 / 10卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

P307

引用

页码：S248 / S249

页数：2

共 50 条

[41] THE EFFICACY AND SAFETY OF ADALIMUMAB FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS AND PREDICTORS OF RESPONSE IN KOREA.
Shin, Seung Yong
Park, Soo Jung
Kim, Young
Im, Jong Pil
Kim, Hyo-Jong
Lee, Kang-Moon
Kim, Ji Won
Jung, Sung-Ae
Lee, Jun
Kang, Sang-Bum
Shin, Sung Jae
Kim, Eun Sun
Kim, You Sun
Kim, Tae Oh
Kim, Hyun Soo
Park, Dongil
Kim, Hyungkil
Kim, Eun Soo
Kim, Dohyun
Teng, Dennis
Kim, Jong-Hwa
Kim, Wonyong
Choi, Chang Hwan
GASTROENTEROLOGY, 2020, 158 (06) : S1206 - S1206
[42] Integrated summary of safety of obefazimod for patients with moderately to severely active ulcerative colitis
Vermeire, S.
Peyrin-Biroulet, L.
Danese, S.
Dubinsky, M.
Dulai, P. S.
Tilg, H.
Siegmund, B.
Hisamatsu, T.
Shan, K.
Jacobstein, D.
Cataldi, F.
Rabbat, C.
Sands, B. E.
JOURNAL OF CROHNS & COLITIS, 2025, 19 : i1554 - i1555
[43] Maintenance Golimumab Treatment in Pediatric UC Patients With Moderately to Severely Active UC: PURSUIT PEDS PK Long-Term Study Results
Hyams, Jeffrey S.
O'Brien, Christopher D.
Padgett, Lakshmi
Rosh, Joel R.
Turner, Dan
Veereman, Genevieve
Griffiths, Anne M.
Heyman, Melvin B.
Wahbeh, Ghassan
Adedokun, Omoniyi J.
Strauss, Richard S.
Lynch, John P.
Chan, Daphne
CROHNS & COLITIS 360, 2020, 2 (04) : 1 - 10
[44] Early Responses in Patient-reported Outcomes Are Predictors for Mucosal Healing in Patients with Moderately to Severely Active Ulcerative Colitis Treated with Golimumab: Results from PURSUIT SC Induction
Sandborn, William
Reinisch, Walter
Feagan, Brian
Marano, Colleen
Strauss, Richard
Han, Chenglong
Johanns, Jewel
Zhang, Hongyan
Gibson, Peter
Collins, Judith
Jarnerot, Gunnar
Rutgeerts, Paul
Colombel, Jean-Frederic
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2013, 108 : S519 - S519
[45] Safety of long-term ozanimod treatment for up to 4 years in patients with moderately to severely active Ulcerative Colitis: an interim analysis of the True North open-label extension
Siegel, C.
Danese, S.
Rubin, D. T.
Sabino, J.
Long, M. D.
Cross, R. K.
Armuzzi, A.
Blumenstein, I.
Kobayashi, T.
Lama, S.
Charles, L.
Cetin, V.
Petersen, A.
Wu, H.
Wang, D.
Jain, A.
D'Haens, G.
JOURNAL OF CROHNS & COLITIS, 2024, 18 : I100 - I101
[46] Safety of Long-Term Ozanimod Treatment Up to 5 Years in Patients With Moderately to Severely Active Ulcerative Colitis: An Interim Analysis of the True North Open-Label Extension
Abraham, Bincy P.
Longman, Randy
Katsanos, Konstantinos
Lee, Scott D.
Kobayashi, Taku
Bettenworth, Dominik
Korman, Louis
Mehra, Dimpy
Santiago, Norma Ruiz
Petersen, Annkatrin
Desai, Manik
Wu, Hsiuanlin
Wang, Dong
Osterman, Mark T.
Jain, Anjali
Torres, Joana
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S1063 - S1063
[47] Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance Studies
Adedokun, Omoniyi J.
Xu, Zhenhua
Marano, Colleen W.
Strauss, Richard
Zhang, Hongyan
Johanns, Jewel
Zhou, Honghui
Davis, Hugh M.
Reinisch, Walter
Feagan, Brian G.
Rutgeerts, Paul
Sandbom, William J.
JOURNAL OF CROHNS & COLITIS, 2017, 11 (01): : 35 - 46
[48] Characterization of Molecular Response to Golimumab in Ulcerative Colitis by mRNA Expression Profiling: Results From Pursuit-SC Induction Study
Li, Katherine
Telesco, Shannon
Rutgeerts, Paul J.
Sandborn, William
Marano, Colleen W.
Ma, Keying
Johanns, Jewel
Zhang, Hongyan
Strauss, Richard
Reinisch, Walter
Colombel, Jean-Frederic
Brodmerkel, Carrie
GASTROENTEROLOGY, 2013, 144 (05) : S465 - S466
[49] Long-Term Safety and Efficacy of Fecal Microbiota Transplant in Active Ulcerative Colitis
Xiao Ding
Qianqian Li
Pan Li
Ting Zhang
Bota Cui
Guozhong Ji
Xiang Lu
Faming Zhang
Drug Safety, 2019, 42 : 869 - 880
[50] Long-term safety and efficacy of filgotinib for the treatment of moderately to severely active ulcerative colitis: Interim analysis from up to 4 years of follow-up in the SELECTION open-label long-term extension study
Feagan, Brian G.
Matsuoka, Katsuyoshi
Rogler, Gerhard
Laharie, David
Vermeire, Severine
Danese, Silvio
Loftus Jr, Edward V.
Beales, Ian
Schreiber, Stefan
Kim, Hyo Jong
Faes, Margaux
de Haas, Angela
Masior, Tomasz
Rudolph, Christine
Peyrin-Biroulet, Laurent
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2024, 60 (05) : 563 - 584

← 1 2 3 4 5 →